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Aberrant Mer receptor tyrosine kinase expression contributes
to leukemogenesis in acute myeloid leukemia
AB Lee-Sherick1, KM Eisenman1,5, S Sather1, A McGranahan2, PM Armistead3, CS McGary3, SA Hunsucker3, J Schlegel1, H Martinson4,
C Cannon1, AK Keating1, HS Earp3, X Liang2, D DeRyckere1 and DK Graham1
Acute myeloid leukemia (AML) continues to be extremely difficult to treat successfully, and the unacceptably low overall survival
rates mandate that we assess new potential therapies to ameliorate poor clinical response to conventional therapy. Abnormal
tyrosine kinase activation in AML has been associated with poor prognosis and provides strategic targets for novel therapy
development. We found that Mer receptor tyrosine kinase was over-expressed in a majority of pediatric (29/36, 80%) and adult
(10/10, 100%) primary AML patient blasts at the time of diagnosis, and 100% of patient samples at the time of relapse. Mer was
also found to be expressed in 12 of 14 AML cell lines (86%). In contrast, normal bone marrow myeloid precursors expressed little
to no Mer. Following AML cell line stimulation with Gas6, a Mer ligand, we observed activation of prosurvival and proliferative
signaling pathways, including phosphorylation of ERK1/2, p38, MSK1, CREB, ATF1, AKT and STAT6. To assess the phenotypic role of
Mer in AML, two independent short-hairpin RNA (shRNA) constructs were used to decrease Mer expression in the AML cell lines
Nomo-1 and Kasumi-1. Reduction of Mer protein levels significantly increased rates of myeloblast apoptosis two to threefold in
response to serum starvation. Furthermore, myeloblasts with knocked-down Mer demonstrated decreased colony formation
by 67–87%, relative to control cell lines (Po0.01). NOD-SCID-gamma mice transplanted with Nomo-1 myeloblasts with reduced
levels of Mer had a significant prolongation in survival compared with mice transplanted with the parental or control cell lines
(median survival 17 days in parental and control cell lines, versus 32–36 days in Mer knockdown cell lines, Po0.0001). These
data suggest a role for Mer in acute myeloid leukemogenesis and indicate that targeted inhibition of Mer may be an effective
therapeutic strategy in pediatric and adult AML.
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INTRODUCTION
Despite significant improvements over the past 30 years, 5-year
survival rates for adults and children with acute myeloid leukemia
(AML) are only around 50–60%,1,2 and those with high-risk
features have a predicted survival of less than 35%.2,3 Using
current therapy, patients with relapsed AML have a survival rate of
less than 30% and frequently do not survive more than 1 year
after relapse diagnosis.4,5 Unfortunately, other than the use of
all-trans retinoic acid in acute promyelocytic leukemia and the
option of hematopoietic stem cell transplantation, there have not
been any new drug approvals or significant changes in AML
therapy in recent years. The toxicity of conventional AML therapy
is often problematic for older adult patients. Additionally,
concerning long-term effects of AML therapy on pediatric and
young adult survivors, include long-term cardiac dysfunction,
cognitive deficits and the occurrence of secondary malignancy.
AML therapy that targets a specific cancer-promoting signaling
pathway could allow a more tailored, efficacious approach leading
to a better clinical response with reduced toxicity.
Recent research in AML has revealed only a few mutated or
aberrantly expressed protein kinases that serve as potential
therapeutic targets. High allelic ratio of the internal tandem
duplication mutation of FLT-3 has been associated with poor
prognosis, and small molecule inhibitors targeting cells which
express FLT-3 have been developed.6,7 C-Kit positive AML, which is
found in a large number of relapsed patients, is associated
with poor prognosis and has also been targeted by small molecule
inhibitors.8,9 Further targeted therapy options are needed
to provide more efficient AML treatment, or allow for a decrease
in high-intensity chemotherapy.
Aberrant expression of the Mer receptor tyrosine kinase has
been detected in several human cancers.10 Preclinical models
have demonstrated that Mer is associated with increased cellular
proliferation, prosurvival and antiapoptotic signaling and
chemoresistance. Mer also exhibits transforming ability in vitro
and in vivo.11–13 Mer is activated by several ligands including Gas6,
which is detectable at significant levels in plasma and bone
marrow, and has been shown to activate PI3K/AKT, ERK1/2 and
NF-kB.14–19 Additionally, Mer activation occurs physiologically in
the context of Gas6 (or other ligand) binding both Mer and
phosphatidyl serine on membrane leaflets of apoptotic cells.
The ubiquitous availability of Gas6 and apoptotic material could
easily stimulate Mer if it is ectopically expressed on malignant
cells. Within the hematopoietic lineage, Mer is normally expressed
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in tissue macrophages, natural killer cells, dendritic cells and
megakaryocytes. Mer is not normally present on cells in any stage
of lymphocyte differentiation; however, ectopic Mer expression in
T-cell lymphoblastic leukemia of childhood has been reported.11
Mer expression in normal myelopoiesis is largely unknown, and its
expression has not been explored in the setting of AML.
In this manuscript we report that Mer is aberrantly
over-expressed in a majority of pediatric and adult AML patient
samples, when compared with normal myeloid progenitors. Mer is
also expressed in the vast majority of AML cell lines. Activation of
Mer in AML cell lines, produced prosurvival and proliferation
signaling, including phosphorylation of ERK1/2 and AKT, as well as
p38 MAPK (p38), MSK1, CREB, ATF1 and STAT6. Lastly, we show
that inhibition of Mer via RNA interference in human AML cell
lines leads to significantly increased apoptosis, decreased colony
forming potential and delayed development of leukemia in
immunocompromised mice. Therapeutically targeting aberrant
Mer expression in AML is attractive, potentially allowing for better
outcomes in high-risk patients, reduced intensity combination
therapy in low-risk patients, or a therapeutic option for those who
cannot tolerate high-intensity chemotherapy.
RESULTS
Mer is aberrantly expressed in AML
To evaluate Mer expression in AML, we assessed 14 different
myeloid cell lines. Mer was detected by immunoblot in the majority
of cell lines analyzed as a 150-180 kD protein (size variation has been
attributed to differential glycosylation18). Flow cytometric analysis
confirmed the findings; cells that were positive for Mer
demonstrated increased fluorescence intensity compared with
mouse immunoglobulin G1 isotype control stained cells, while
negative cells did not (Figure 1 and Supplementary
Table S1). Our analysis revealed a high degree of correlation
between immunoblot and flow cytometric results, and indicated
there was some degree of Mer expression in 86% (12 of 14) of AML
cell lines. In this cell line analysis, Mer expression was not associated
with any French-American-British (FAB) or World Health Organiza-
tion (WHO) classification, cytogenetic abnormality, age of the patient
from which the cell line was derived, nor did it correlate with other
known clinical features (Supplementary Table S1).
Several AML bone marrow or peripheral blood samples from
newly diagnosed patients were analyzed in the same manner, using
both immunoblot and flow cytometric analysis. These samples also
indicated a high degree of correlation between the whole-cell Mer
protein levels visualized on immunoblot and the cell surface
expression of Mer demonstrated by flow cytometry, thus we
initiated a prospective analysis of newly diagnosed patient samples
using flow cytometry alone. Parallel samples were stained with a
primary Mer antibody or isotype control, and a secondary antibody.
Gating was performed on cells stained with the IgG1 isotype control
antibody and secondary antibody, in order to ensure that non-
specific antibody binding was excluded from our analysis
(Figure 2a). Using this gating strategy, we defined samples that
had greater than 20% cells shifted out of the isotypeþ secondary
antibody gating area as ‘Mer-positive’, and samples with 10–20%
cells shifted out of the gate as ‘Mer-dim.’ Samples that had less than
10% of cells shifted were termed ‘Mer-negative,’ though samples in
this category may still have some low level of Mer expression.
Samples were evaluated at their respective institutions using this
flow cytometric gating strategy within 24 h of bone marrow or
peripheral blood collection. In total, we assessed 36 newly
diagnosed pediatric samples and 10 newly diagnosed adult
samples (Figure 2b and Supplementary Table S2). Approximately
80% (29 of 36) of samples from newly diagnosed pediatric AML
patients, and 100% (10 of 10) of samples from newly diagnosed
adult AML patients expressed Mer on leukemic blasts (that is, were
Mer-positive or Mer-dim). In addition, 100% (10 of 10 pediatric, and
1 of 1 adult) of samples from patients who relapsed or had disease
that was refractory to induction therapy expressed Mer; the
majority of these exhibited high levels of cell surface Mer
(Supplementary Table S3). There was also a trend towards higher
Mer expression in pediatric relapsed and refractory patient samples
when compared with the same patient’s diagnostic sample; this did
not reach statistical significance due to low-sample size.
Importantly, in the data presented, flow cytometry was
performed within 24 h of patient sample collection. Frozen AML
patient samples obtained from the Children’s Oncology Group,
which were collected and frozen at inconsistent time points, were
subjected to both immunoblot and flow cytometric analysis
(Supplementary Figures S1A and B) and showed decreased
cell surface Mer expression relative to the samples which were
processed within hours of acquisition (Supplementary Figure S1C).
Additional control experiments revealed that Mer expression
diminished significantly when patient samples were incubated
at room temperature for extended periods (Supplementary
Figure S1D). Furthermore, freezing and thawing patient samples
also decreased surface Mer expression (data not shown). Mer is
subject to extracellular domain cleavage and therefore loss of the
Mer antibody epitope when cleavage occurs. After 36 h at room
temperature, protein cleavage, as well as protein degradation,
may contribute to the need to analyze fresh samples.
In contrast to the easily detectable Mer expression in AML
blasts, Mer was not detected or detected only at low levels on the
cell surface of normal myeloid progenitors. Bone marrow samples
from eight healthy donors were obtained and flow cytometry
performed within 24 h of collection. Cells were stained with CD34,
CD33 and CD14 fluorophore-conjugated antibodies to evaluate
each stage of myeloid maturation. Myeloblast and monoblast
populations were defined as CD34þ /CD33þ , promyelocytes and
promonocytes were defined by high forward scatter and CD33
high/CD14 , and monocytes were defined as CD33 high/
CD14þ . Mer surface expression by flow cytometry was analyzed
Figure 1. Mer is expressed in AML cell lines. (a) Whole-cell lysates
derived from AML cell lines were subjected to immunoblot analysis
with an anti-Mer antibody. This representative blot shows detection
of the Mer protein (150–180 kD) in several AML cell lines. Actin was
detected as a loading control. (b) Cell surface expression of Mer was
determined by flow cytometry after staining with an anti-human
Mer primary antibody and a PE-conjugated secondary antibody
(gray histogram). Non-specific staining was determined using an
IgG1 isotype control primary antibody and PE-conjugated secondary
antibody (white histogram). Representative Mer negative (HL-60)
and Mer positive (KG-1) cell lines are shown.
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using gating as described above excluding non-specific binding of
the secondary antibody. Using this gating strategy, only 1.7% of
promonocytes and 4.3% of monocytes were Mer expressing
(Figure 2c), thus being classified as Mer-negative (o10% Mer
positive). It was not possible to accurately determine Mer
expression for the normal marrow myeloblast/monoblast popula-
tions. Though several of these samples appeared to have no Mer
expression, due to the extremely low cell number (203–865 total
CD34þ /CD33þ cells per sample), we cannot exclude the
possibility that this population contains some level of Mer
expression.
Mer activates prosurvival and antiapoptotic cellular pathways
To assess the function of Mer signaling in AML cells, we
investigated downstream signaling pathways in two Mer expres-
sing AML cell lines, which are negative for tyrosine kinase family
members Tyro-3 and Axl: Nomo-1 and Kasumi-1 (Figure 3a).
These cell lines were selected as representative of two different
AML subtypes; Nomo-1 was derived from an adult acute
monoblastic leukemia and Kasumi-1 was derived from a pediatric
acute myeloblastic leukemia, with granulocytic maturation.
Serum-starved Nomo-1 and Kasumi-1 cells were stimulated with
Gas6 (a known Mer ligand), and phosphorylation of Mer was
confirmed by immunoprecipitation (Figure 3b). A phospho-kinase
array was used to screen for activation of signaling pathways
following stimulation of AML cells with Gas6, compared with
buffer-treated cells. Two independent replicates were performed,
and relative changes in phosphorylation were determined.
Following Gas6 treatment, the arrays suggested a 1.5-fold or
greater increased phosphorylation of MSK1, AMPKa, AKT, mTOR,
CREB, SRC family kinases SRC, LYN, YES, FGR and HCK, and STAT6
(Figures 3c and d). Immunoblot analysis was used to confirm
phosphorylation of these proteins and was also used to assess
several other downstream signaling candidates, including ERK1/2,
p38 and AFT1, after Gas6 stimulation (Figure 3e). We confirmed
previous analysis, which demonstrated phosphorylation of ERK1/2,
AKT and p38 in response to Mer activation but stimulation
of MSK1, CREB, ATF1 and STAT6 phosphorylation revealed new
potential pathways downstream of Mer. These data indicate the
potential for Mer activation to contribute to malignant cell survival
and proliferation (Figure 3f).
Mer inhibition with Mer shRNA knockdown
To study the functional role of Mer in AML, we introduced short-
hairpin RNA (shRNA) directed against Mer into the two cell lines
used above. Nomo-1 and Kasumi-1 were transduced with
lentivirus encoding one of two different shRNA constructs (shMer1
and shMer4) to decrease Mer expression, or a non-silencing shRNA
(shControl), and stable clones were developed. Immunoblot
analysis of whole-cell lysates was performed to assess the efficacy
of Mer inhibition. Both knockdown clones efficiently decreased
expression of Mer, with the shMer4 clone of each cell line having
slightly more efficient Mer knockdown than the shMer1 clone
(Figure 4a). These findings were confirmed by flow cytometric
analysis for cell surface Mer expression, which demonstrated
efficient knockdown for both constructs, with slightly more
inhibition in cells with shMer4 (70–80% knockdown) than shMer1
(60% knockdown) compared with shControl (Figure 4b).
Mer inhibition using shRNA decreases p38, ERK and CREB
phosphorylation
To assess which downstream pathways were most affected by Mer
inhibition using shRNA, we further analyzed the proteins which
demonstrated increased phosphorylation after Gas6 stimulation
(that is, MSK1, p38, ERK, AKT, CREB, ATF1 and STAT6) using
our Mer knockdown Nomo-1 and Kasumi-1 cell lines. When serum-
starved cells were stimulated with Gas6, knockdown cell lines
consistently demonstrated a concomitant decrease in phosphory-
lation of p38, ERK and CREB, compared with those treated with
buffer alone (Figure 4c).
Inhibition of Mer induces apoptosis myeloblasts in vitro
The phenotypic effects of Mer inhibition in AML were assessed
in vitro. Nomo-1 and Kasumi-1 cells with or without the shRNA
Figure 2. Mer is expressed in a majority of diagnostic bone marrow
samples derived from patients with AML, but not in normal bone
marrow. Myeloblasts collected at diagnosis from patients with AML
were analyzed by flow cytometry for Mer expression. (a) Cells that
expressed human CD33 and CD45 were analyzed after staining
with a mouse anti-human Mer antibody and PE-conjugated
secondary antibody to determine Mer expression (gray histogram).
Non-specific staining was determined using a mouse IgG1 isotype
control antibody and PE-conjugated secondary antibody (white
histogram). Representative flow cytometry profiles for Mer-positive
(420% cells positive), Mer-dim (10–20% cells positive) and
Mer-negative (o10% cells positive) patient samples are shown.
(b) Graphic representation showing the fractions of Mer-positive,
Mer-dim and Mer-negative pediatric (right panel) and adult (left
panel) diagnostic primary patient samples. (c) Bone marrow samples
from eight healthy donors were evaluated by flow cytometry for Mer
RTK expression as described above. Myeloid progenitor populations
were identified by gating on the cell surface markers noted in the
figure. The fractions of cells expressing Mer in progenitor popula-
tions are shown. Myelo/monoblastic populations could not be
quantified, due to low-cell number.
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constructs were stained with Yo-Pro-1 iodide and propidium
iodide after 18 h of serum starvation, and subjected to flow
cytometric analysis. Cells taking up Yo-Pro-1 iodide alone
(early apoptosis), and those taking up both Yo-Pro-1 iodide and
propidium iodide (late apoptosis and necrosis) were included in
the analysis; cells taking up only propidium iodide (dead cells)
were excluded to eliminate the possibility of analyzing cells that
had died before analysis. Cell lines with reduced levels of Mer
demonstrated a higher degree of apoptosis; B35% (shMer1) and
55% (shMer4) of cells were considered apoptotic in response to
serum starvation. This was significantly greater than the 15–20%
apoptosis observed in control cell lines (Po0.05 and Po0.01,
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Figures 5a and b). The increase in apoptosis correlated with the
level of Mer knockdown; cells containing the shMer4 construct
exhibited more apoptosis (B50–60%) than those containing
shMer1 (B35%).
Inhibition of Mer decreases proliferation of myeloblasts in vitro
To assess another malignant characteristic of myeloid leukemia
cells, the shMer1, shMer4 or shControl cells were evaluated for
colony forming potential. Cells were plated in equal number in
methylcellulose, and myeloblast colony formation was assessed
after 13 days. Compared with control cell lines, AML cell lines with
reduced levels of Mer demonstrated a 67–87% decrease in total
colony forming units (Po0.01, Figures 6a, b and d).
Reintroduction of Mer rescues myeloblast ability to evade
apoptosis and form colonies
Kasumi-1 shMer1 cells were transduced with a retroviral vector
containing a wild-type (WT) Mer gene (shMer1þMer WT), a kinase
domain mutant Mer gene (shMer1þMer K619R), or a green
fluorescence protein gene (shMer1þNTV) (Figure 5c). Apoptosis
was analyzed by flow cytometric analysis of the shControl and
shMer1 cell lines along with the Mer WT add-back and K619R
mutant Mer cell lines after 18 h serum starvation, as described
above. Cells containing the green fluorescence protein were
excluded in this assay due to fluorophore interference with the
Yo-Pro-1 iodide. Reintroduction of WT Mer protein rescued the
myeloblast’s ability to evade stress-induced apoptosis to levels
comparable to shControl cells (difference not significant), which
was a significant decrease in apoptosis compared with shMer1
cells (Po0.05, Figure 5d). In contrast, shMer1 cells containing the
Mer K619R kinase mutant demonstrated apoptosis levels similar to
shMer1 (difference not significant). Additionally, Kasumi-1
shMer1þMer WT, shMer1þMer K619R and shMer1þNTV cells
were analyzed in methylcellulose. Reintroduction of WT Mer
rescued the myeloblast’s ability to form colonies comparable to
parental and shControl cells (difference not significant, Figures 6b
and c), which was a significant increase in the number of colonies
formed compared with shMer1þMer K619R and shMer1þNTV
control cells (Po0.01) and shMer1 (Po0.01).
Mer inhibition increases leukemia-free survival in vivo
A mouse xenograft model of AML was developed to explore how
decreased Mer expression affects myeloblast survival in vivo.
Sublethally irradiated NOD-SCID-gamma mice were injected
intravenously with the parental Nomo-1 cell line or Nomo-1 cell
lines containing shControl or shMer constructs. Following injection
of leukemic cells, mice were monitored for clinical signs of
leukemia (weight loss exceeding 15% of body weight, inability to
move effectively, lethargy). When mice became ill or at the end of
the experiment (45 days post-injection) they were euthanized and
relevant tissues were extracted. Single cell suspensions were
prepared, stained with antibodies specific for human leukocyte
markers, and analyzed by flow cytometry to confirm engraftment.
Engraftment was defined as greater than 20% CD33þ and
CD45þ cells in the bone marrow and/or spleen (data not shown).
Symptom-free survival was determined for all mice with
confirmed engraftment, and Kaplan–Meier curves demonstrated
a statistically significant prolongation in survival (Po0.0001,
Figure 7) in mice injected with Nomo-1 Mer knockdown cells
relative to those injected with parental or shControl cells (median
survival for parental and shControl was 17 days, 32 days for
shMer1 and 36 days for shMer4).
DISCUSSION
We demonstrate here that the Mer tyrosine kinase is over-
expressed in the vast majority of AML cell lines and leukemic
patient AML blasts, when compared with the level of Mer
expression in myeloid precursors from normal bone marrow.
Mer was found on the surface of 80–100% of adult and pediatric
patient samples at diagnosis, independent of the FAB, WHO or
cytogenetic risk classification. Additionally, Mer cell surface
expression appears to be higher in AML patient samples at the
time of relapse or induction failure, though this data set is too
small to determine statistical significance. The relation of Mer to
patient prognosis was not determined in this study as the recent
sample collection makes the time to follow-up insufficiently short
to observe clinical course and relapse for the majority of our
patients. Collection of samples from patients with AML and
analysis of Mer expression is ongoing in order to address this
question more effectively.
In contrast, normal promonocytes and monocytes in the bone
marrow express undetectable to minimal levels of Mer. Though
we were not able to fully determine the extent of Mer expression
of myeloblasts and monoblasts, genetic loss of Mer in myeloid
progenitors does not appear to have major clinical consequences,
based on the observation that Mer knock-out mice exhibit no
deleterious effects on myeloid cell production.20
The mechanism of Mer over-expression in AML is not clear;
possible mechanisms include adaptations at the level of
transcription or translation such as altered promoter methylation
or microRNA regulation. Increased expression of Axl, another
member of the Tyro-3/Axl/Mer tyrosine kinase family, in myeloid
leukemia after treatment with chemotherapy has been found to
be coincident with increased Axl promoter methylation.21 In
breast cancer, silencing of Mer-suppressive microRNA has been
associated with increased metastasis.22 Abnormal Mer expression
in leukemia has not yet been linked to specific epigenetic
alterations, and further evaluation of the mechanism of Mer over-
expression in AML is warranted.
Figure 3. Mer stimulation in AML cells activates oncogenic signaling pathways. (a) Immunoblot analysis of Kasumi-1 and Nomo-1 cell lines
confirmed they were positive for Mer (B180 kD), but negative for other Tyro-3/Axl/Mer family tyrosine kinases Axl (140 kD) and Tyro-3
(140 kD). (b) Kasumi-1 and Nomo-1 cells were incubated in serum-free RPMI medium then treated with 200 nM rhGas6 (Gas6 treated) or buffer
(Untreated). Immunoprecipitate analysis demonstrating phosphorylation of Mer after 200 nM Gas6 treatment (þ ) compared with treatment
with buffer ( ). Total Mer was used as a loading control. (c) Similarly treated diluted lysates were incubated with human phospho-kinase array
membranes and bound phospho-proteins were detected according to kit instructions. Each membrane contains positive control (P)
antibodies spotted in duplicate. Proteins which demonstrated a 1.5-fold or greater increase in phosphorylation after stimulation with Gas6
(Gas6 treated) relative to buffer treated (Untreated) are marked by numbers between duplicate spots, which correlate with the identification
numbers shown in (d). (d) Levels of the indicated phospho-proteins were quantified after normalizing pixel density of each positive control to
100. Untreated samples are denoted in white, and Gas6 treated cells are denoted in gray hatched lines, showing the difference in relative
phosphorylation between the two conditions. Each bar represents the mean±s.e. of duplicate spots. Increases were found in levels of
phosphorylated MSK1 (S376/S360), AMPKa (T174), AKT (S473), mTOR (S2448), CREB (S133), SRC family kinases SRC (Y419), LYN (Y397),
YES (Y426), FGR (Y412) and HCK (Y411) and STAT6 (Y641). (e) Kasumi-1 and Nomo-1 cells were incubated in serum-free media for 2–3 h
followed by treatment with 200 nM rhGas6 (þ ) or buffer ( ). Whole-cell lysates were subjected to immunoblot analysis with antibodies
specific for the phosphorylated and total MSK1, p38, ERK1/2, STAT6, AKT, ATF1 and CREB proteins. Representative Nomo-1 immunoblot shown
here. (f ) Oncogenic downstream signaling pathways found to be activated in Mer-positive AML cells following stimulation with Gas6.
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Mer activation in AML cell lines stimulates prosurvival pathways
that are known to be important in AML pathogenesis.
These studies demonstrate that Gas6 stimulated Mer-expressing
AML cell lines increased phosphorylation of ERK1/2 and AKT,
confirming earlier findings that these pathways are downstream
of Mer in other cancer types.10 Previous studies have emphasized
the importance of the ERK1/2 and AKT pathways in maintenance
of myeloblast survival, proliferation and evasion of apoptosis.23,24
Our work also demonstrates several signaling molecules, which
have not been previously described downstream of Mer and/or in
Mer-positive human leukemias including p38, MSK1, CREB,
ATF1 and STAT6. Activation of p38 has previously been
described downstream of a Mer chimeric receptor consisting
of the extracellular and transmembrane epidermal growth
factor receptor domains and the Mer cytoplasmic domain.25
Downstream of ERK1/2 and p38, MSK1 has been associated with
malignant proliferation in AML,26 but has not previously been
assessed as a part of the Mer signaling cascade in malignancy.
Activation of the ERK1/2 and p38 pathways in these AML cell lines
by Gas6 ultimately led to phosphorylation of transcription factors
CREB and ATF1, which have not previously been reported as part
of Mer signaling. Phosphorylation and over-expression of CREB
has been described in adult and pediatric AML, and has been
linked to abnormal proliferation and survival of myeloid cells, and
poor prognosis.27–29 Similar in function to CREB, the ATF1
transcription factor has rarely been assessed in AML, though its
activation has been associated with poor prognosis in AML in one
study.30 STAT6 is a member of a family of transcription factors that
regulate cellular processes such as proliferation, differentiation
and survival. STAT6 deficiency has been associated with increased
numbers of committed myeloid progenitors in the bone
marrow,31 suggesting the possibility that STAT6 activation
maintains myeloid progenitor immaturity. These data expand
our knowledge of Mer activation by Gas6, suggesting a
mechanism for proliferation and survival in myeloblasts.
Also reported here are the effects that inhibition of Mer has on
myeloblast survival and proliferation in vitro and on leukemogen-
esis in vivo. Using shRNA, we effectively decreased Mer protein
levels. This in turn decreased myeloblast cell line ability to stave
off starvation-induced apoptosis, indicating that Mer functions to
promote survival in AML cells. Consistent with this observation,
colony formation in methylcellulose was also decreased in AML
cells expressing shMer. Most importantly, reducing Mer expression
significantly prolonged survival in a mouse model of AML.
Interestingly, our data show correlation between Mer levels and
phenotypes; whole-cell lysate and surface Mer expression was
reduced to a greater extent in the shMer4 clone and had a greater
effect on these measured phenotypes than the shMer1 clone.
These results suggest that development of therapies directed
against Mer should aim for the most effective degree of inhibition.
Additionally, we demonstrate that when Mer knockdown cell lines
are stimulated with Gas6, there was a decrease in phosphorylation
of p38, ERK and CREB. These data suggest that these pathways
may contribute to the growth and proliferation differences
observed between the WT and shControl cell lines, and the shMer
knockdown cell lines in our experiments.
These results also suggest that AML cell lines are reliant on Mer
signaling to sustain viability under stress and in vivo. Additionally,
these data demonstrate a rationale for anti-Mer targeted therapy
in both adult and pediatric AML. Potentially, Mer inhibition could
have a clinically significant effect in patients at both ends of the
AML age spectrum, as either monotherapy or in combination with
current AML therapies.
Currently, there are a few translational agents targeting Mer in
preclinical development. One of these is a recently described Mer
monoclonal antibody, which showed decreased tumor migration
and survival in glioblastoma multiforme cell lines.32 There are also
selective Mer small molecule tyrosine kinase inhibitors in early
development that effectively decrease Mer phosphorylation
in vitro and in vivo.33
Our data provide proof of concept that Mer is a therapeutic
target in AML and will likely lead to further development of Mer
Figure 4. Mer protein expression is reduced by shRNA expression in
AML cell lines. Kasumi-1 and Nomo-1 cells were infected with
lentiviral particles containing short hairpin RNA (shRNA) constructs
targeting Mer (shMer1, shMer4), or GFP as a non-silencing control
(shControl). Knockdown of Mer was confirmed by (a) immunoblot
analysis of whole-cell lysates and (b) flow cytometry using anti-Mer
antibody. Values represent means and s.e. derived from three
independent experiments. (c) Kasumi-1 and Nomo-1 parental and
shRNA containing cells were incubated in serum-free media for 2–3h
followed by a 10min treatment with 200 nM rhGas6 ((þ ) Gas6) or
buffer (Serum Starved). Whole-cell lysates were subjected to
immunoblot analysis with antibodies specific for the phosphory-
lated and total proteins analyzed in Figure 3e. Of those, p38, ERK1/2,
and CREB consistently demonstrated decreased phosphorylation
corresponding to level of Mer, when stimulated with Gas6.
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targeted agents, including additional antibodies and/or specific
small molecule inhibitors. These novel therapies have the
potential to impact patients with AML, as well as patients with
other malignancies characterized by Mer dependency, and may
provide a means to improve survival with decreased toxicity
relative to current standard chemotherapeutic regimens.
MATERIALS AND METHODS
Patient samples and cell culture
Bone marrow or peripheral blood samples were obtained from the
Children’s Hospital Colorado Oncology Tissue Bank, the University of North
Carolina Hematolymphoid Malignancies Tissue Procurement Facility, or the
Children’s Oncology Group repository of AML patient samples.
De-identified primary patient samples were collected after written consent
was obtained in accordance with the Declaration of Helsinki, and all
experiments were approved by the Colorado Multiple Institutional Review
Board or the University of North Carolina Office of Human Research Ethics
Institutional Review Board. AML samples that were analyzed when left out at
room temperature were resuspended in 800ml complete RPMI, then evenly
distributed into four tubes (accounting for 12, 24, 36 and 48 h time points).
When cells were harvested, both the cell pellet and supernatant were
treated with lysis buffer as describe below (Immunobloting and Signaling
Assays). Equal quantities of supernatant were loaded into SDS-polyacryla-
mide gel electrophoresis gels, though no loading protein was detected.
Cell lines EOL-1, HEL, HL-60, K-562, KG-1, ML-2, MV4-11, NB-4, Nomo-1,
OCI-AML3, THP-1 and UT-7 were obtained from the German Collection of
Microorganisms and Cell Culture (DSMZ, Braunschweig, Germany); Kasumi-1
and U-937 were obtained from the American Type Culture Collection
(Manassas, VA, USA); Molm14 was a gift from Robert Arceci (Johns Hopkins,
Baltimore, MD, USA). All cell lines except UT-7 were maintained in RPMI 1640
media (Sigma, St Louis, MO, USA) supplemented with 10% fetal bovine
serum (FBS) and penicillin-streptomycin at 37 1C in 5% CO2; UT-7 was
maintained in 80% alpha-MEM with 5 ng/ml granulocyte-macrophage
colony-stimulating factor and 20% FBS. For apoptosis and proliferation
assays, cells were maintained in culture at logarithmic growth phase. All
human cell lines were subjected to genomic fingerprinting via short tandem
repeat microsatellite loci analysis to verify their identity.
Flow cytometry
At relapse or induction failure, flow cytometry was performed on patient
bone marrow or peripheral blood within 24 h of sample collection at the
institution ,in which the patient was diagnosed using identical protocols
and antibodies. Pediatric samples were obtained and flow cytometric
analysis performed at the Children’s Hospital Colorado. Adult samples were
obtained at the North Carolina Cancer Hospital and flow cytometric
analysis performed at Lineberger Comprehensive Cancer Center. Samples
were prepared using Immunoprep Reagent System (Beckman Coulter,
Brea, CA, USA) or Ficoll-Paque separation. Cells were then stained with a
mouse-anti-human Mer antibody or mouse IgG1 isotype control, washed
with phosphate-buffered saline (PBS), stained with a PE conjugated
donkey-anti-mouse secondary antibody, washed with PBS, stained with
anti-human CD33 and anti-human CD45 fluorophore-conjugated anti-
bodies, washed with PBS, then analyzed. During flow cytometric data
acquisition, patient blasts populations (CD33þ /CD45þ ) were indentified,
and from these populations gating was set using the sample stained with
Figure 5. Mer knockdown confers susceptibility to apoptosis. (a)
Parental, non-silencing control shRNA (shControl) and Mer knock-
down (shMer1, shMer4) Kasumi-1 and Nomo-1 cells were serum
starved or cultured in complete medium for 18 h before staining
with propidium iodide and Yo-Pro-1 iodide. Apoptotic cells were
identified by flow cytometry. Representative flow cytometry profiles
are shown. The percentages of early apoptotic (lower right
quadrant; Yo-Proþ /PI ) and late apoptosis/necrosis (upper right
quadrant; Yo-Proþ /PIþ ) cells are shown. (b) Cumulative data
demonstrate a significant accumulation of apoptotic cells in Kasumi-
1 and Nomo-1 cells when Mer is inhibited by shRNA knockdown
(*Po0.05 and **Po0.01 versus shControl). No significant differences
between parental and shControl cells were observed. (c) Reintro-
duction of WT Mer into Kasumi-1 shMer1 knockdown cells rescues
Mer protein level after knockdown (shMer1þMer WT). Additional
control cell lines were generated by transduction of a gene for a
kinase mutant Mer (shMer1þMer K619R), which maintains the
extracellular epitope that binds the anti-Mer antibody, or a non-
targeting vector (shMer1þNTV) into Kasumi-1 shMer1 cells.
Representative immunoblot of Mer protein levels shown here.
(d) Apoptosis of Kasumi-1 WT add-back (shMer1þMer WT) and
mutant Mer add-back (shMer1þMer K619R) cells were analyzed in
comparison to shControl and shMer1 cells after serum starvation as
described above. Mer WT add-back rescues myeloblast ability
to stave off apoptosis comparable to shControl cell lines
(NS¼ not significant compared to shControl, *P¼ 0.05 compared
with shMer1 and shMer1þK619R). Mean values and s.e. derived
from at least three independent experiments are shown.
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mouse IgG1 isotype control and PE secondary, such that two percent or less
of the cells were outside the gating area. This gate was then applied to the
patient sample stained with the Mer primary and PE secondary antibodies
to determine the percent of cells expressing Mer. When assessing normal
bone marrow samples, myeloid progenitor cells were identified by serial
gating using forward and side scatter, CD33, CD34 and CD14 surface
expression. Three populations were identified: CD34þ , CD33þ and
CD14 myeloblasts and monoblasts; high forward scatter, CD34þ / ,
CD33 high and CD14 promyelocytes and promonocytes; and CD34 ,
CD33 high and CD14þ monocytes. AML cell lines were assessed after
staining with either a mouse IgG1 isotype control or a mouse anti-human
Mer antibody and APC conjugated donkey-anti-mouse secondary antibody.
The following antibodies were used for flow cytometric analysis of cell
surface proteins: CD33 PE-Cy7, CD34 FITC (BD Biosciences, San Jose, CA,
USA); CD45 PE-Texas Red, CD14 PE-Cy5 (Beckman Coulter); donkey-anti-
mouse APC, donkey-anti-mouse PE (Jackson ImmunoResearch, West Grove,
PA, USA); mouse IgG1 isotype control (R&D Systems, Minneapolis, MN, USA).
Additionally a mouse-anti-human Mer monoclonal antibody (Mer 590)
produced by the Graham laboratory as previously described32 was used for
all flow cytometric analysis of Mer expression. Fluorescence was assessed
and analyzed using an FC-500 flow cytometer (Beckman Coulter) for
pediatric patient and normal marrow samples, a MACSQuant flow
cytometer (Miltenyi Biotec Inc., Cambridge, MA, USA) for adult patient
samples, or a Gallios flow cytometer (Beckman Coulter) for cell lines, with
CXP data analysis software (Beckman Coulter).
Immunoblotting and signaling assays
R&D Systems Human Phospho-Kinase Antibody Array (ARY003) was used
to detect relative changes in kinase phosphorylation. Cells were plated at
Figure 6. Mer knockdown decreases AML colony forming potential. Parental, non-silencing control shRNA (shControl), and Mer knockdown
(shMer1, shMer4) Nomo-1 and Kasumi-1 cells were cultured in methylcellulose for 13 days. (a) Images of representative plates from
the Nomo-1 cell line are shown. (b and d) Total colony number was determined demonstrating a statistically significant decrease in
colony formation when Mer is inhibited (**Po0.01). (c) When Mer is reintroduced into shMer1 cells, colony forming potential is restored to
shControl levels seen in (b) (difference not significant), which does not occur when Mer K619R mutant (shMer1þMer K619R) or non-targeting
vector (shMer1þNTV) are introduced into shMer1 cells (**Po0.01). Mean values and s.e. derived from at least three independent experiments
are shown.
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3 106 in RPMI without FBS for 2–3 h, and treated with 200 nM
recombinant human Gas6 (R&D Systems) or buffer for 10 min at room
temperature. Remaining steps were performed according to manufacturer
instructions. To determine relative changes in phosphorylation between
buffer-and Gas6-treated cells, densities of individual spots were measured
using ImageJ software (National Institutes of Health). For immunoblots,
whole-cell lysates were prepared in a lysis buffer containing 50 mM HEPES
(pH 7.5), 150 mM NaCl, 10 mM EDTA, 10% (v/v) glycerol, 1% (v/v) Triton
X-100, 1 mM sodium orthovanadate, 0.1 mM sodium molybdate and
protease inhibitors (Roche Diagnostics, Indianapolis, IN, USA). Lysates
were incubated on ice for 15–20 min, then protein supernatant was
collected after centrifugation. Lysates were resolved on 8% Tris-Glycine
SDS-polyacrylamide gel electrophoresis gels (Invitrogen, Grand Island,
NY, USA) and transferred onto polyvinylidene difluoride membranes.
Membranes were blocked in a buffer of tris buffered saline with 0.1%
Tween-20 containing 5% milk. The following antibodies were used for
immunoblot analysis according to manufacturer recommendations: anti-
human Mer (Epitomics Inc., Burlingame, CA, USA); anti-human Axl (R&D
Systems); anti-Actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA); anti-
Tyro-3, anti-phospho-p44/42 MAPK (ERK1/2, Thr202/Tyr204), anti-p44/42
MAPK, anti-phospho-p38 MAPK (Thr180/Tyr182), anti-p38 MAPK, anti-
phospho-MSK1 (Ser376), anti-MSK1, anti-phospho-AKT (Ser473), anti-AKT,
anti-phospho-CREB (Ser133), anti-CREB, anti-phospho-STAT6, anti-STAT6
(Tyr641) (Cell Signaling Technology, Danvers, MA, USA); anti-ATF1 (Up-state
Millipore, Billerica, MA, USA); goat-anti-mouse IgG-HRP, goat-anti-rabbit
IgG-HRP (BioRad, Hercules, CA, USA). Proteins were visualized by
horseradish peroxidase chemiluminescence detection (Perkin-Elmer,
Waltham, MA, USA).
Immunoprecipitation
Cells were plated at 3 106 in RPMI without FBS for 2–3 h, treated with
200 nM recombinant human Gas6 (R&D Systems) or buffer for 4 min, then
1:100 diluted hydrogen peroxide (a mild phosphatase inhibitor) was added
for an addition 4 min. Cells were then resuspended in lysis buffer as
described above. Anti-human Mer antibody (R&D Systems) and rec-Protein
G-sepharose beads (Invitrogen) were then added, and lysates were
incubated overnight on a rocking platform. Cells were washed twice, then
resolved on 8% SDS-polyacrylamide gel electrophoresis gels, and
transferred onto nitrocellulose membranes. Membranes were blocked in
tris buffered saline with 0.1% Tween-20 containing 5% milk, then probed
with an anti-phospho-Mer antibody (Phosphosolutions, Aurora, CO, USA).
Membranes were then stripped and reprobed for anti-human Mer
(Epitomics).
Production of shRNA clones
Two independent shRNA constructs targeting human Mer (shMer1,
shMer4) and one non-silencing control shRNA construct directed against
GFP (shControl) were used as previously described.34 The shMer1 construct
compliments the 30 untranslated region of the Mer RNA, whereas the
shMer4 sequence complime0nts the kinase-encoding region of the RNA.
Stable clonal lines were derived from heterogeneous Mer knockdown
populations by single-cell flow cytometry sorting. The shMer1 and shMer4
clones were selected for decrease in Mer expression. The shControl
clone was selected for similar Mer expression to the parental cell line.
Additionally, Kasumi-1 shMer1 clones were used to reintroduce WT Mer
protein levels (shMer1þMer WT) using pLNCX2 add-back vectors
(Clontech, Mountain View, CA, USA) which lack the 30 untranslated
region to evade shMer1 binding, as previously described.32,35 Similarly,
shMer1 cells were transduced with pLNCX2 vectors coding for Mer with a
kinase domain mutation (shMer1þMer K619R) or green fluorescence
protein (shMer1þNTV) as controls.
Apoptosis and cell survival assays
Cells were counted by trypan blue exclusion using a Cedex XS Analyzer
(Roche Applied Science). For apoptosis assays following shRNA knock-
down, cells were cultured in medium with or without serum for 18 h. Cells
were collected, washed twice with PBS and stained with propidium iodide
and Yo-Pro-1-iodide (Invitrogen). The percentage of apoptotic cells
was determined by flow cytometry using a FC-500 flow cytometer.
For methylcellulose colony forming assays, cells were plated in triplicate at
a density of 500 cells/plate in Colony Gel Human Base Medium
methylcellulose (Reach Bio, Seattle, WA, USA) with RPMI media containing
10% FBS added per manufacturer instructions. Plates were incubated for
13 days at 37 1C with 5% CO2, and colonies were counted using a GelCount
automated colony counter (Oxford Optronix, Oxford, UK).
Mouse xenograft studies
Six- to 10-week-old NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NOD-scid-gamma)
mice were obtained from the Jackson Laboratory (Bar Harbor, ME, USA) or
bred in-house and maintained under sterile conditions. Animals were
irradiated with 200 cGy using a RS-2000 irradiator (Rad Source, Suwanee,
GA, USA) within 24 h before tail vein injection with 5 106 viable human
Nomo-1 AML cells in 0.1 ml sterile PBS. Mice were monitored daily and
weighed twice weekly. Once mice appeared clinically ill or lost 415% of
their body weight, they were euthanized and peripheral blood, bone
marrow, spleen and any tumors or involved lymph nodes were harvested.
Presence of AML was confirmed by flow cytometry after staining with
anti-human CD45 FITC and CD33 PE-Cy7 conjugated antibodies (BD
Biosciences). All experiments were conducted under the supervision of
the facility’s Institutional Animal Care and Use Committee according to an
Institutional Animal Care and Use Committee–approved protocol.
Statistical analysis
Analysis was performed using Graphpad Prism 4 Software (La Jolla, CA,
USA). Phospho-kinase array data represent means of two independent
replicates of each cell line. Remaining in vitro data represent means of
at least three independent replicates, and a paired t-test was used to
compare knockdown samples to control shRNA samples. In vivo survival
curve data were analyzed using a log-rank test. Results were considered
statistically significant if the P-value was calculated at less than 0.05.
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